Emergent BioSolutions Inc.
HealthcareNYSE:EBS · New York Stock Exchange
-$0.07 today
Vol 0.40M · Avg 0.75M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$676.8M of revenue converted into -$8.6M of net income for the selected period. Gross margin is 42.8% and net margin is -4.7%, showing how much revenue survives after costs and taxes. EPS is $-0.28, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $742.9M -28.8% | $1.0B -0.5% | $1.0B -6.1% | $1.1B -37.0% | $1.8B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $392.3M -41.3% | $668.2M -3.1% | $689.3M +7.0% | $644.5M -34.3% | $980.4M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $350.6M -6.6% | $375.4M +4.3% | $360.0M -23.9% | $473.0M -40.4% | $793.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 47.2% +11.2pp | 36.0% +1.7pp | 34.3% -8.0pp | 42.3% -2.4pp | 44.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $53.8M -23.9% | $70.7M -36.5% | $111.4M -40.8% | $188.3M -19.9% | $235.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $186.6M -37.5% | $298.7M -16.3% | $356.7M +5.1% | $339.5M -2.6% | $348.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $240.4M -50.3% | $484.1M -55.4% | $1.1B +69.0% | $643.0M +42.3% | $451.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $98.3M -6.9% | $105.6M -12.8% | $121.1M -3.1% | $125.0M +5.8% | $118.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | $240.4M +350.2% | $53.4M +213.6% | -$47.0M -399.4% | $15.7M -96.9% | $504.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 32.4% +27.2pp | 5.1% +9.6pp | -4.5% -5.9pp | 1.4% -27.0pp | 28.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $110.2M +201.4% | -$108.7M +85.0% | -$726.4M -327.3% | -$170.0M -149.8% | $341.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 14.8% +25.2pp | -10.4% +58.8pp | -69.2% -54.0pp | -15.2% -34.5pp | 19.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $59.3M -16.5% | $71.0M -19.2% | $87.9M +135.7% | $37.3M +8.1% | $34.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$27.4M +19.9% | -$34.2M -612.5% | -$4.8M +90.2% | -$49.0M -28.3% | -$38.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $82.8M +157.9% | -$142.9M +80.5% | -$731.2M -233.9% | -$219.0M -172.2% | $303.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 11.1% +24.8pp | -13.7% +56.0pp | -69.7% -50.1pp | -19.6% -36.7pp | 17.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $30.2M -36.7% | $47.7M +62.8% | $29.3M +495.9% | -$7.4M -108.8% | $83.7M | $1.3B | -$1.6B | $745.2M |
| Net Income | $52.6M +127.6% | -$190.6M +74.9% | -$760.5M -259.4% | -$211.6M -196.4% | $219.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | 7.1% +25.3pp | -18.3% +54.2pp | -72.5% -53.5pp | -18.9% -31.3pp | 12.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +127.2% | -$4 +75.8% | -$15 -251.9% | -$4 -202.9% | $4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +125.8% | -$4 +75.8% | -$15 -251.9% | -$4 -203.9% | $4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $53.5M +0.9% | $53.0M +3.5% | $51.2M +2.2% | $50.1M -6.4% | $53.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $56.7M +7.0% | $53.0M +3.5% | $51.2M +2.2% | $50.1M -7.4% | $54.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
COMPASS Pathways plc
NASDAQ:CMPS
$1.16B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Esperion Therapeutics, Inc.
NASDAQ:ESPR
$654.91M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$414.11M
SNDL Inc.
NASDAQ:SNDL
$369.44M
SIGA Technologies, Inc.
NASDAQ:SIGA
$309.85M
Organogenesis Holdings Inc.
NASDAQ:ORGO
$301.10M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does EBS generate?
Emergent BioSolutions Inc. (EBS) reported $742.90M of revenue in fiscal 2025.
Is EBS profitable?
Emergent BioSolutions Inc. (EBS) reported $52.60M of net income, with a net margin of 7.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.